null

MONMOUTH JUNCTION, NJJuly 22, 2021 -- Biotech Support Group reports on a journal article describing the simplicity and efficiency of their HemogloBind™ sample preparation technology for quantitative LC-MS multiple reaction monitoring (MRM) analysis. The study provides methods for the accurate, reliable, and confirmatory identification of bodily fluids commonly encountered in a forensic context. The citation is:

 

Heather E. McKiernan, Phillip B. Danielson, Catherine O. Brown, Masha Signaevsky, Christian G. Westring and Kevin M. Legg, Developmental Validation of a Multiplex Proteomic Assay for the Identification of Forensically Relevant Biological Fluids, Forensic Science International, (2021)

https://www.sciencedirect.com/science/article/pii/S0379073821002280?via%3Dihub

 

The aim of this study was to validate a multiplex proteomic assay for the identification of target peptide fragments by multiple reaction monitoring on a triple quadrupole mass spectrometer originating from tissue-specific proteins. Samples came from peripheral blood, semen, saliva, urine, and vaginal/menstrual fluid. To remove the highly abundant amount of Hemoglobin in some samples, the article states “If samples contained excessive quantities of hemolyzed red blood cells, four volumes of HemogloBind™ were added.” The authors conclude that the mass spectrometry-based workflow offers significant advantages compared to existing serological methods.

 

“The large amount of hemoglobin in many forensic samples presents a special challenge for quantitative analysis. This is another example demonstrating again that HemogloBind™ can reduce the interference associated with large concentrations of hemoglobin, without compromising the recovery and analysis of the target peptide(s)/protein(s) of interest.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

 

Click here for more information on HemogloBind™

Click here for more information on all of our Hemoglobin Removal products


About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients.